Publications du laboratoire
Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD) - Archive ouverte HAL
Article Dans Une Revue Thrombosis and Haemostasis Année : 2022

Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD)

1 IThEM - U1140 - Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis
2 FAC - CMI - Fondation Alain Carpentier - (Centre Médical International) [Paris]
3 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
4 Innovte - F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne]
5 PhysMed Paris - Physique pour la médecine
6 Centre hospitalier Saint-Joseph [Paris]
7 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
8 CHU Amiens-Picardie
9 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
10 TIMC - Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525
11 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
12 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
13 CIC Brest - Clinique d'Investigation Clinique
14 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
15 PCVP / CARDIO - Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920)
16 CRESS (U1153 / UMR_A 1125) - Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques
17 UPD5 - Université Paris Descartes - Paris 5
18 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
19 UGA - Université Grenoble Alpes
20 CIC 1418 - CIC - HEGP

Résumé

Introduction: D-dimer measurement is a safe tool to exclude pulmonary embolism (PE) but its specificity decreases in COVID-19. Our aim was to derive a new algorithm with specific D-dimer threshold in COVID-19 patients. Methods: We conducted a French multicenter, retrospective cohort study among 774 COVID-19 patients with suspected PE. D-dimer threshold adjusted to computed tomography (CT) extent of lung damage was derived in a patient set (n=337), and its safety assessed in an independent validation set (n=337). Results: According to ROC curves, in the derivation set D-dimer safely excluded PE, with one false negative when using a 900 ng/mL threshold when lung damage extent was <50% and 1700 ng/mL when lung damage extent was ≥50%. In the derivation set, the algorithm sensitivity was 98.2% (95% CI: 94.7–100.0) and its specificity 28.4% (95% CI: 24.1–32.3). The negative likelihood ratio (NLR) was 0.06 (95% CI: 0.01–0.44) and the area under the curve (AUC) was 0.63 (95% CI: 0.60–0.67). In the validation set, sensitivity and specificity were 96.7% (95% CI: 88.7–99.6) and 39.2% (95% CI: 32.2–46.1), respectively. The NLR was 0.08 (95% CI; 0.02–0.33) and the AUC did not differed from that of the derivation set (0.68 ,95% CI: 0.64–0.72, P = 0.097). Using the Co-LEAD algorithm, 76/250 (30.4%) COVID-19 patients with suspected PE could have been managed without CT pulmonary angiography (CTPA). Conclusion: The Co-LEAD algorithm safely excludes PE, and allows reducing the use of CTPA among COVID-19 patients. Further prospective studies are necessary to validate this strategy.

Fichier principal
Vignette du fichier
main.pdf (1.24 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-03722805 , version 1 (07-09-2024)

Licence

Identifiants

Citer

Benjamin Planquette, Lina Khider, Alice Le Berre, Simon Soudet, Gilles Pernod, et al.. Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD). Thrombosis and Haemostasis, 2022, 122 (11), pp.1888-1898. ⟨10.1055/a-1768-4371⟩. ⟨hal-03722805⟩
796 Consultations
235 Téléchargements

Altmetric

Partager

  • More